METHODS: This retrospective cohort study included patients who underwent NAC-IDS (first-line treatment) at Kurume University Hospital, Japan, between 2004 and 2017. CRS association with MDR1 and CA125 KELIM was examined using Cox proportional hazard regression analyses. Survival curves used Kaplan-Meier method, and survival differences between groups used log-rank test.
RESULTS: Overall, 55 patients were classified into CRS1 (n=22), CRS2 (n=19), and CRS3 (n=14). The CRS3 group had a significantly better prognosis than the CRS1 or CRS2 group. CRS, age, and IDS status were clinical prognostic factors for ovarian cancer. MDR1 positivity for excision repair cross-complementing group 1, β-tubulin, and Y-box binding protein-1 occurred in 15, 17, and 11 patients, respectively, but these were not associated with CRS. CA125 KELIM was <0.5 (n=8), 0.5-1.0 (n=30), and ≥ 1.0 (n=17) but not associated with CRS.
CONCLUSIONS: CRS is reconfirmed as a treatment response predictor for NAC-IDS, but its association with drug resistance factors remains unconfirmed.
方法:这项回顾性队列研究包括在库鲁米大学医院接受NAC-IDS(一线治疗)的患者,Japan,2004年至2017年。使用Cox比例风险回归分析检查CRS与MDR1和CA125KELIM的相关性。生存曲线采用Kaplan-Meier法,组间生存差异采用对数秩检验。
结果:总体而言,55例患者分为CRS1(n=22),CRS2(n=19),和CRS3(n=14)。CRS3组的预后明显优于CRS1或CRS2组。CRS,年龄,和IDS状态是卵巢癌的临床预后因素。切除修复交叉互补组1的MDR1阳性,β-微管蛋白,Y盒结合蛋白-1发生在15、17和11例患者中,分别,但这些与CRS无关。CA125KELIM<0.5(n=8),0.5-1.0(n=30),≥1.0(n=17),但与CRS无关。
结论:CRS被再次确认为NAC-IDS的治疗反应预测因子,但其与耐药因素的关联仍未得到证实。